133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T+64 4 496 2000
21 March 2022
Kiwi Angel
By email: [FYI request #18804 email]
Ref:
H202203698
Tēnā koe
Response to your request for official information Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of
Health (the Ministry) on 7 March 2022 for information about the Pfizer COVID-19 Comirnaty
vaccine. Specifically, you asked:
“I would like information and correspondence in regards to the Pfizer papers released last
week reporting on the results of serious Adverse Events Data and deaths from MRNA
vaccine. There are 9 pages of side-effects, long term damage and death. 1,223 deaths
fatalities during a three month period and 42,000 reported adverse events. This data
shows a 3% fatality rate which is seen as extremely high in terms of vaccine efficacy.
As a concerned mother I would like a copy of any correspondence the MOH has relating
to these Pfizer Papers. Also papers & correspondence relating to the latest research out
of Sweden on Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA
Vaccine BNT162b2 In Vitro in Human Liver Cell Line.”
The Ministry has interpreted your request for information about “the Pfizer papers” to be about
the
Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048
(BNT162B2) Received Through 28-Feb-2021 (hereafter the Cumulative Analysis Report) that
was published in the United States last year. The Ministry received numerous requests about
the genesis of the Cumulative Analysis Report and has published responses to three of them on
its website. They are available under the 12 January 2022 publication date for
Information on
Pfizer Cumulative Analysis Report at:
www.health.govt.nz/about-ministry/information-
releases/responses-official-information-act-requests. Your request is therefore refused under
section 18(d) of the Act on the grounds that the information sought is publicly available.
Regarding your request for information about research conducted in Sweden, the Ministry’s
COVID-19 Science and Technical Advisory Group advises that the study was flawed by its use
of a liver cancer cell line that bears little resemblance to normal healthy human cells. While the
Ministry will continue to monitor information on this issue, it advises that to date no researchers
have been able to provide robust genomic evidence of reverse transcription of RNA and DNA
integration into human genomes.
Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any
decisions made under this request. The Ombudsman may be contacted by email at:
[email address] or by calling 0800 802 602.
Please note that this response, with your personal details removed, may be published on the
Ministry website at:
www.health.govt.nz/about-ministry/information-releases/responses-official-
information-act-requests. Nāku noa, nā
Jan Torres
Acting Manager, OIA Services
Office of the Director-General
Page 2 of 2
